← Browse COAs·Confirmed by BioRegen

Verifiable directly with BioRegen— this report is hosted on the lab's own portal. Click through to view the canonical version, served by the issuing lab.

Composite COA score

68/ 100Grade D

View original COA How this is scored →Score JSON ↗

Avg purity

Safety panel

Lab corroboration

Forgery risk

Ipamorelin

Lot 29-3-46035 · tested by BioRegen · 2026-01-29 · sold by BioLongevity Labs

View all IpamorelinCOAs & purity data →

Scan or share

www.disclosedlabs.com/coa/cmojb6u5h0166kirx1mcxbgkh

99.54%

Purity

3.30 mg

Net peptide

✓

Mass spec

—

Endotoxin

Tests reported

HPLC purity

99.540%

Mass spec / LC-MS

Reported

FTIR identity

—

Endotoxin (LAL)

—

Tested by

BioRegen

149 COAs indexed · std dev 0.25% · US

Source

We discovered this COA on the vendor's public site.

First indexed 2026-04-29 · extracted 2026-05-24

View original

Embed this COA on a product page

Vendors who reference this batch can drop a one-line script. The verified-COA badge renders inline and the QR scans back to this page.

<script src="https://www.disclosedlabs.com/widget.js" data-lot="29-3-46035"></script>

Label history

No archived listing available for this COA's test date.

Observed signals

criticalIn our analysis, lot "29-3-46035" appears on 2 different peptides at BioLongevity Labs: ipamorelin, tesamorelin. A lot number normally identifies a single manufacturing batch of one compound, so this pattern can indicate recycled lab data — or a vendor reusing one identifier across a multi-product shipment. Flagged from the COAs available to us; vendors may contest this.

This certificate is third-party content submitted by a vendor or laboratory, or collected from a public source; Disclosed Labs does not author it and does not warrant its accuracy or authenticity. Any signals or scores shown are our opinion based on the data available to us. If you are the vendor or issuing lab and believe this report is inaccurate, forged, or should be removed, request a correction or removal — see our Copyright & Takedown Policy.